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effect (3.2, 2.5-4.2) respectively. The SI score for interaction was 3.6 (95% CI: 3.1-4.2).
Conclusions: Our study demonstrates that a familial propensity to SCA interacts with
presence of increasing metabolic RF, magnifying the risks for those exposed to both.
1028-168 Is Asymmetric Dimethylarginine a Marker for Diabetes, 
Coronary Artery Disease, and Death/Myocardial 
Infarction? Results of the Intermountain Heart 
Collaborative Angiographic Registry Study
Jeffrey L. Anderson, John F. Carlquist, William L. Roberts, Benjamin D. Horne, Tami L. 
Bair, Elisabeth L. Schwarz, Marzia Pasquali, Joseph B. Muhlestein, LDS Hospital, Salt 
Lake City, UT, University of Utah, Salt Lake City, UT
Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric
oxide synthase that has generated interest as a potential cause or marker of endothelial
dysfunction and its clinical consequences, including diabetes, coronary artery disease
(CAD), and renal failure.
Methods: We tested whether ADMA distinguishes patients (pt) with normal (NFG; <110
mg/dL), or impaired fasting glucose (IFG; 110-125), and diabetes (DM; >126 mg/dL);
angiographic CAD; and death (D) or nonfatal myocardial infarction (MI) in a case-control
cohort of 442 pt selected from the 3 glycemic categories from among 3000 pt entered in
the Intermountain Heart Collaborative Registry. Consenting pt had fasting blood drawn
for FG and ADMA during angiographic assessment and were followed for 2.6 ± 1.4 y.
ADMA was assayed from cryogenically stored samples by high-pressure liquid chroma-
tography with pre-column derivitzation and fluorescence detection. Non-parametric (KW)
testing compared ADMA among groups. Logistic regression was used for predictive mod-
eling.
Results: The study cohort consisted of equal numbers with NFG (146), IFG (148), and
DM (148), matched for age (±5 y) and gender. Overall, age averaged 61 years; 72% were
male; 24%, smokers; 68% had angiographic CAD; 61%, hypertension; 58%, hyperlipi-
demia; 24%, prior MI. During follow-up, 137 events occurred. Distribution of ADMA was
broad and rightward skewed, with median 0.85 µM (range, 0-30). Mean (median) ADMA
levels increased progressively by glycemic category (p<0.001): NFG=2.3 (0.74), IFG=3.0
(0.77), DM= 3.4 (1.27). When adjusted for standard risk factors, CAD severity, and pre-
senting diagnosis, ln ADMA independently predicted DM (odds ratio [OR] 1.29 /ln unit, CI
1.07-1.54, p=0.006) and, less strongly, CAD (OR 1.21, CI 1.0-1.5, p=0.06). Ln ADMA
trended higher in those with D/MI (adjusted OR 1.17, CI 0.98-1.39, p=0.08).
Discussion: Among a high coronary risk case-control cohort, ↑ADMA predicted ↑risk of
IFG, DM, and CAD. Thus, ADMA might contribute to endothelial dysfunction associated
with these conditions. Further research should determine whether ADMA is a causal fac-
tor or passive marker and determine causes of interpatient variability.
1028-169 The Predictive Value of Parental History of Coronary 
Disease
Pamela Ouyang, Lisa R. Yanek, Daniele Fallin, Taryn F. Moy, Lewis C. Becker, Diane M. 
Becker, Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins 
University Bloomberg School of Public Health, Baltimore, MD
Background: Parental history of coronary disease (CHD) is a well-known risk factor for
CHD. However the risk conferred by the gender of an affected parent is controversial and
data are sparse. This prospective study in high risk families was designed to determine
the extent to which a maternal or paternal history of CHD contributed independently to
the risk of incident CHD after adjusting for known risk factors.
Methods: Unaffected siblings (SIBS) of probands were identified from hospitalized index
cases with a documented CHD event < 60 years of age. This prospective analysis
includes 345 women and 339 men with either maternal, paternal or no parent with history
of CHD. Parental family history was elicited by self-report and confirmed by another fam-
ily member. SIBS were followed for incident CHD events. SIB events were documented
by medical records and adjudicated by an external endpoints committee.
Results: The 684 SIBS were 46±7 yrs old at baseline, 50% female, 21% African Ameri-
can, 32% smokers, 7% diabetics, 43% hypertensives, and 67% hypercholesterolemic.
Incident CHD occurred in 84/684 (12.3%) of all SIBS over 8.7±3.2 yrs follow-up. Incident
events occurred in 12.9% of SIBS with no parental history, 10.5%; of sibs with a paternal
history only, and 14.8% of SIBS with a maternal CHD history only. In a Cox proportional
hazard analysis predicting incident CHD in SIBS, the multivariate adjusted relative risk for
maternal CHD was 2.05 (95% CI=1.15-3.65) and for paternal history was 1.0 (95%
CI=0.6-1.66), controlling for age, SIB sex, race, hypertension, current smoking, LDL cho-
lesterol, diabetes, obesity and education.
Conclusion: Among individuals with a documented family history of premature CHD,
having a maternal history of CHD was most strongly associated with the highest risk of a
CHD event. Controlling for known risk factors, maternal history alone conferred a signifi-
cant and independent excess risk of incident CHD whereas paternal alone history was
not significant.
1028-170 Higher Levels of Lipoprotein-Associated Phospholipase 
A2 Are Associated With Higher Incidence of 
Cardiovascular Events at Follow-Up Independent of C-
Reactive Protein
Emmanouil S. Brilakis, Joseph P. McConnell, Jr., Ryan J. Lennon, Ahmad A. Elesber, 
Jeffrey G. Meyers, Peter B. Berger, Mayo Clinic, Rochester, MN
Background: Limited data exist on the association between lipoprotein-associated phos-
pholipase A2 (Lp-PLA2) with cardiovascular risk.
Methods and Results: We measured Lp-PLA2 levels in 504 consecutive patients under-
going clinically indicated coronary angiography. Mean age was 60±11 years and 38%
were women. The mean (± SD) Lp-PLA2 level (ng/mL) was 245 ± 91. Median C-reactive
protein (CRP, mg/L) was 0.29 (interquartile range: 0.12, 0.67). During a median follow-up
of 4.0 years, 58 cardiovascular events occurred in 49 of 466 contacted patients (11%):
cardiac death in 6, acute myocardial infarction (AMI) in 14, coronary revascularization in
28, and stroke in 10. Higher Lp-PLA2 levels were associated with a greater risk of cardio-
vascular events: the hazard ratio (HR) per standard deviation was 1.31 (p=0.010), and
remained significant after adjusting for clinical (age, gender, smoking, hypertension) and
lipid (total and HDL cholesterol, Lp(a), and triglycerides) variables and CRP (Table).
Conclusion: Higher Lp-PLA2 levels were associated with a higher incidence of cardio-
vascular events at follow-up, independently of traditional coronary artery disease risk fac-
tors and CRP.
1028-171 Fasting Blood Glucose: An Underestimated Risk Factor 
for Subclinical Coronary Atherosclerosis
Khurram Nasir, Roger S. Blumenthal, Joel B. Braunstein, Romeu Meneghello, Jose A. 
Maluf, Wendy S. Post, Matthew J. Budoff, Raul D. Santos, Johns Hopkins Medical 
Institutions, Baltimore, MD, Albert Einstein Hospital, Sao Paulo, Brazil
Background: Non-diabetic individuals with high fasting blood glucose (FBG) are at high
risk for experiencing the metabolic syndrome, which includes insulin resistance, hyper-
tension, dyslipidemia, and a procoagulant state. While emerging evidence suggests that
impaired FBG (FBG_110 mg/dl) may accelerate atherosclerosis, we sought to evaluate
the independent impact of FBG in the upper normal range (<110 mg/dl) as a risk factor
for subclinical coronary atherosclerosis assessed by coronary artery calcification (CAC)
in an asymptomatic non-diabetic population.
Methods : We studied 531 consecutive asymptomatic, non-diabetic males (46±7 yrs;
range 29-65 yrs) with FBG<110 mg/dl in the study who presented for electron-beam
computed tomography (EBCT) between 1999 and 2002 in Sao Paulo, Brazil. The popula-
tion was divided into 2 categories; highest quartile of FBG (>85 mg/dl, n=119) and the
lowest three quartiles (n=412).
Results:Individuals in the highest quartile of FBG were more likely to have higher body
mass index (28±4 vs. 26±3, p<0.0001), waist to hip ratio (0.99±0.06 vs. 0.93±0.06,
p=0.01), triglycerides (410±116 vs. 180±92, p=0.05) and systolic blood pressure (131±14
vs.121±13, p<0.0001), where as no significant difference was observed in high density
lipoprotein, low density lipoprotein and total cholesterol levels respectively. Overall
median, 75th percentile and 90th percentile CAC scores were: 3, 24 and 156 among indi-
viduals with highest FBG quartile compared to 0, 6 and 56 among patients with lowest
three quartiles (p<0.05). After adjusting for potential cofounders, the odds ratio for any
calcification (CAC>0) with FBG>85 mg/dl was 2.5 (95% CI=1.1-5.4, p=0.02) and 1.8 (1.1-
3.2, p=0.01) for >75th percentile CAC, respectively
Conclusions: FBG in the upper normal range (>85 mg/dl) appears to be an important
independent predictor of presence and severity of CAC in non-diabetic apparently
healthy young/middle aged men.
1028-172 Increased Urinary 8-Iso-Prostaglandin F2alpha 
Excretion Predict Cardiac Events in Patients With Type 
2 Diabetes
Yusuke Nakagawa, Yoshiyuki Kijima, Akira Nishibe, Nobuyuki Ogasawara, Tamayo 
Ishiko, Megumi Kunishige, Takeshi Hata, Higashiosaka City General Hospital, 
Higashiosaka, Japan
Background: Increased oxidant stress may play a key role in the etiology of diabetic car-
diovascular complications. We hypothesized that increased production of 8-iso-prostag-
landin F2alpha (8-iso-PGF2alpha), a marker for in vivo oxidant stress, predicts future
cardiac events in type 2 diabetic patients.
Methods: We studied 148 patients aged 30-85 (62±10) with type 2 diabetes. Baseline
level of urinary 8-iso-PGF2alpha excretions were measured and the patients were fol-
lowed up for a mean period of 1380 days. Cardiac events were defined as hospitalization
for acute myocardial infarction, unstable angina, revascularization, and worsening heart
failure.
Results: One hundred thirty-nine patients completed the follow-up, while 2 died of non-
cardiac causes. Of the remaining 137 patients, cardiac events were occurred in 16. Uri-
nary 8-iso-PGF2alpha excretion above the median value of 287.5 pg/mg creatinine was
Multivariate association between Lp-PLA2 and CRP with cardiovascular events at 
follow-up.
Endpoint Lp-PLA2
HR (95% confidence 
intervals)
logCRP
HR(95% confidence 
intervals)
Cardiac Death + AMI 1.31 (0.94, 1.81) 1.14 (0.73, 1.79)
Cardiac Death + AMI + Stroke 1.33 (1.02, 1.74) 1.26 (0.86,1.84)
Cardiac Death + AMI + 
Revascularization
1.25 (0.96, 1.64) 1.20 (0.88, 1.64)
Cardiac Death + AMI + 
Revascularization + Stroke
1.29 (1.02, 1.63) 1.26 (0.95, 1.67)
All-Cause Death + AMI 1.30 (1.01, 1.67) 1.35 (0.96, 1.89)
All-Cause Death + AMI + Stroke 1.32 (1.06, 1.65) 1.39 (1.03, 1.89)
All-Cause Death + AMI + 
Revascularization
1.28 (1.02, 1.61) 1.30 (0.99, 1.70)
All-Cause Death + AMI + 
Revascularization + Stroke
1.31 (1.06, 1.60) 1.34 (1.04, 1.72)
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associated with higher incidence of cardiovascular events (20% vs. 4%, p=0.004). Previ-
ous cardiovascular disease, defined as history of ischemic heart disease and/or periph-
eral vascular disease, was also associated with higher incidence of cardiovascular
events (25% vs. 6%, p=0.003). Urinary 8-iso-PGF2alpha excretion above the median
value was associated with cardiovascular events in this high-risk group (43% vs. 5%,
p=0.007), but was not in the remaining “low-risk” diabetic patients (9% vs. 4%). In Cox
regression analysis adjusting for age, gender, body mass index, glycemic control, and
traditional risk factors, urinary 8-iso-PGF2alpha excretion (p=0.01) and previous cardio-
vascular disease (p=0.04) were independent predictors of cardiac events.
Conclusion: Increased urinary 8-iso-PGF2alpha excretion predicts cardiac events in
patients with diabetes, especially in the group with overt cardiovascular disease. These
results suggest that the assessment of urinary 8-iso-PGF2alpha excretion has clinical
implications as a tool for risk stratification in patients with type 2 diabetes.
1028-173 Association Between Cardiorespiratory Fitness and C-
Reactive Protein in Young Adults
Michael J. Williams, Barry J. Milne, Robert J. Hancox, Richie Poulton, University of 
Otago, Dunedin, New Zealand
Background: Physical activity is associated with a lower risk of cardiovascular disease
but the mechanisms remain uncertain. Inflammatory markers are predictive of cardiovas-
cular risk. We therefore examined the association between cardiorespiratory fitness and
C-reactive protein (CRP) in a group of young adults.
Methods: Cardiorespiratory fitness using a bicycle ergometer, blood pressure, smoking
history, and anthropometric measurements were determined in 308 women and 399 men
aged 26 years. Maximal heart rate during submaximal exercise was used to calculate
VO2 max. (ml/kg/min). Subjects were classified in tertiles of physical fitness according to
VO2 max. level. CRP was measured using an immunoturbidimetric assay.
Results: Geometric mean (95% CI) CRP levels were significantly related to levels of car-
diorespiratory fitness in men (p<0.01) and women (p<0.001). 
There was a significant fitness × sex interaction (p= 0.01) indicating the relationship was 
stronger for women. When adjusted for body mass index, blood pressure and smoking 
history the relationship was significant for women only.
Conclusions: CRP level is independently related to cardiorespiratory fitness in young 
women.
1028-174 Increased Subclinical Atherosclerosis in Young Adults 
With Metabolic Syndrome: The Bogalusa Heart Study
Wendy S. Tzou, Maureen E. Mays, Pamela S. Douglas, Sathanur R. Srinivasan, Wei 
Chen, Gerald S. Berenson, James H. Stein, University of Wisconsin, Madison, WI, 
Tulane University, New Orleans, LA
Background
Metabolic Syndrome (MetS) is associated with subclinical atherosclerosis and increased
cardiovascular risk in older and middle-aged adults, however these associations have not
been studied among young adults. Carotid intima-media thickness (CIMT) is a validated
measure of atherosclerosis that predicts cardiovascular events. The purpose of this study
was to determine if MetS is associated with increased CIMT in young adults.
Methods
Non-diabetic subjects from the Bogalusa Heart Study, a longitudinal study of the natural
history of atherosclerosis in young adults and children (20-38 years old), underwent high-
resolution B-mode ultrasound imaging of the carotid arteries to determine site-specific
and composite CIMT values. Presence of MetS was determined using the NCEP Adult
Treatment Panel III definition. Logistic regression analyses were performed to determine
if MetS was associated with increased CIMT.
Results
Of 506 subjects (mean age 32 years, 29% black, 39% male), 67 (13%) had MetS. CIMT
values were significantly higher among subjects with MetS (table). The prevalence of
MetS increased with CIMT (ptrend = 0.0028). Odds ratios (95% confidence intervals) for
the presence of MetS in subjects with CIMT >0.8 mm and >1.0 mm were 4.8 (1.7-13.7)
and 8.0 (2.0-32.8), respectively.
Conclusions
Even in young adults, MetS is associated with increased carotid atherosclerosis, empha-
sizing the importance of early screening and treatment in this population.
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1029-175 Anti-ErbB2 Modulation of Bcl-xL/Bcl-xS Causes 
Mitochondrial Dysfunction and Apoptosis
Luanda Grazette, Wolfgang Boecker, Marc Semigran, Tom Force, Roger J. Hajjar, 
Anthony Rosenzweig, Massachusetts General Hospital, Boston, MA
Background
ErbB2 is a co-receptor and important signal integrator for the EGF family of receptor
tyrosine kinases.Over expression of erbB2 occurs in many cancers. A monoclonal anti-
body inhibiting erbB2 is a potent chemotherapeutic agent but is associated with cardiac
toxicity. Here we investigate the effects of anti-erbB2 antibody on cardiomyocyte survival
and mitochondrial function.
Methods and Results
Primary cultures of neonatal were exposed to anti-erbB2 antibody (anti-erbB2 Ab 5-7.5
µg/ml) for up to 24 hours. Cell viability, mitochondrial function, and apoptosis were mea-
sured using multiple complementary techniques. Selected studies were confirmed in pri-
mary cultures of adult rat cardiomyocytes.
ErbB2 inhibition was associated with a dramatic increase in expression of the pro-apop-
totic Bcl-2 family protein, Bcl-xS, and decreased levels of pro-survival Bcl-x. There was a
time dependent increase in mitochondrial translocation and oligomerization of the mito-
chondrial pore former, BAX, as indicated by BMH crosslinking. Bax oligomerization was
associated with release of cytochrome c and activation of caspase 9.
This alteration of Bcl-2 family signaling induced mitochondrial dysfunction evident as a
loss of mitochondrial membrane potential (delta psi) as measured by JC-1 red fluores-
cence on fluorescent plate reader (5242 ± 191 vs 4606 ± 87 p<.05 N=6) and by fluores-
cent flow cytometry of mitotracker stained NRVM (76.85 ± 2.4 vs 51.7 ± .072 p<.05 N=4).
There was also a 35% decline in ATP level (p<.05) as measured by luciferin-luciferase
bioluminescence and a loss of redox capacity as measured by MTT (.7224 ± .036 vs
.6421 ± .017 p<.01).
Restoration of Bcl-xL levels through TAT-mediated transduction prevented the decline in
delta psi;, MTT activity and cytosolic ATP.
Anti-erbB2 Ab treatment resulted in a modest increase in apoptosis as measured by
TUNEL (6.5± 0.7 vs 3.1 ± 0.4%. p<.05) and propidium iodide flow cytometry( 8.3±0.9 vs
4.5±0.6 % p<.01)
Conclusion
Anti-erbB2 activates the mitochondrial apoptosis pathway through direct modulation of
bcl-xL and bcl-xS and causes impairment of mitochondrial function, integrity, cellular
energetics and low level apoptosis.
1029-176 Rescue of Internalization-Impaired Angiotensin II AT1 
Mutants by β-Arrestin Overexpression
Chris E. Kule, Vijaya Karoor, Jonathan N. E. Day, Walter G. Thomas, Kenneth M. Baker, 
Kathleen A. Acker, George W. Booz, Texas A&M Univ., College of Medicine, Temple, TX
The pathophysiological effects of Angiotensin II (Ang II) are mostly mediated by the G-
protein coupled type 1 receptor (AT1), which internalizes upon Ang II binding. Recently,
β-arrestin was shown to play a role in AT1 endocytosis by binding the cytoplasmic, C-ter-
minus region T332-S338, the major site of Ang II-induced phosphorylation. The process
responsible for recruiting β-arrestin to the activated receptor has not been defined. Using
CHO-K1 and HEK 293 cells to express wild type or mutant AT1, we investigated whether
T332-S338 phosphorylation is a prerequisite for β-arrestin-dependent AT1 internaliza-
tion. We first established that phosphorylation of this region is important for AT1 internal-
ization in our cells. Substitution of T332, S335, T336 and S338 with alanine to preclude
phosphorylation, markedly attenuated AT1 internalization, while replacement of these
sites with acidic residues glutamate (E) and aspartate (D) to mimic phosphorylation, par-
tially rescued internalization. We next assessed the ability of β-arrestin overexpression to
rescue agonist-induced internalization of phosphorylation-impaired receptors. β-arrestin
1 or 2 overexpression enhanced internalization of the TSTS/A mutant, with β-arrestin 2
having the more pronounced effect. β-arrestin 2, alone or with β-arrestin 1, increased the
rate of TSTS/A internalization towards that of wild-type AT1. The TSTS/ED mutant was
also responsive to β-arrestin 1 or 2 expression. These findings indicate that a signal
besides C-terminus phosphorylation is responsible for recruiting β-arrestin to AT1. How-
ever, ligand-induced phosphorylation of AT1 likely facilitates receptor internalization by
enhancing β-arrestin binding.
Cardiorespiratory fitness Males
(n=399)
Females
(n=308)
Unfit 2.06 (1.69-2.49) 4.31 (3.57-5.17)
Intermediate 1.61 (1.34-1.92) 3.76 (2.97-4.70)
Fit 1.46 (1.18-1.77) 1.94 (1.53-2.42)
Mean Carotid IMT Values (mm, standard deviation)
MetS
Present
MetS
Absent
Punadjusted P adjusted for 
age, sex, race, 
and smoking
Composite 0.780 + 0.130 0.728 + 0.097 0.0005 0.0016
Common Carotid 0.699 + 0.108 0.659 + 0.084 0.0008 0.0012
Bulb 0.922 + 0.211 0.852 + 0.174 0.0037 0.0222
Internal Carotid 0.721+ 0.206 0.676 + 0.121 0.0202 0.0384
